Brind.

Glaukos markets FDA-approved corneal cross-linking therapy, with management attending a conference in Boston.

6 reports, 3 independent Updated Aug 17
Gone quiet Reached 2 outlets in its first 24 hours
Reports
6
Developments
3
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Glaukos markets FDA-approved corneal cross-linking therapy, with management attending a conference in Boston.

Who's involved

What this event is mainly about
GlaukosFDA

How it developed

Newest first. Tap a step to see who reported it.
  1. Glaukos device achieves commercial availability in Canada and Australia; FDA submission supported.1 source
  2. Glaukos markets FDA-approved corneal cross-linking therapy and holds investor relations activities.1 source
  3. Glaukos reported a 41% YoY surge in U.S. glaucoma sales on July 9, 2025.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • ocbj.com
  • ocbj.comGlaukos Completes Enrollment for Glaucoma Implant Study - Orange County Business Journal
  • Business WireGlaukos Announces Participation in Wells Fargo Healthcare Conference ALISO VIEJO, Calif., August 13, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical
  • Business WireGlaukos Announces Second Quarter 2025 Financial Results ALISO VIEJO, Calif., July 30, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology comp
  • ZacksGlaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks Glaukos Corporation GKOS continues to reshape the ophthalmology landscape, backed by a record-breaking first-quarter 2025 performance
  • Unknown outlet